Clinical Trial Update: A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating metronomic low-dose treosulfan, pioglitazone, and clarithromycin versus standard treatment in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-squamous Cell Lung Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)
• Treosulfan (treosulfan)
• clarithromycin (clarithromycin)

Snippet

Sponsor: University Hospital Regensburg | Conditions: Squamous Cell Lung Cancer, Non-Squamous Cell Lung Cancer | Phase 2 | Status: UNKNOWN